Equities research analysts forecast that Bioline RX Ltd (NASDAQ:BLRX) will post ($0.07) earnings per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Bioline RX’s earnings. Bioline RX reported earnings per share of ($0.08) in the same quarter last year, which would suggest a positive year over year growth rate of 12.5%. The firm is scheduled to issue its next earnings report on Thursday, May 24th.
On average, analysts expect that Bioline RX will report full year earnings of ($0.31) per share for the current fiscal year, with EPS estimates ranging from ($0.34) to ($0.28). For the next year, analysts forecast that the firm will report earnings of ($0.33) per share, with EPS estimates ranging from ($0.37) to ($0.28). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow Bioline RX.
Several equities analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Bioline RX from a “hold” rating to a “sell” rating in a report on Thursday, March 8th. HC Wainwright reissued a “buy” rating and set a $4.00 price objective on shares of Bioline RX in a report on Tuesday, March 6th. Oppenheimer assumed coverage on shares of Bioline RX in a report on Thursday, December 21st. They set a “buy” rating and a $3.00 price objective on the stock. Maxim Group set a $3.00 price objective on shares of Bioline RX and gave the company a “buy” rating in a report on Monday, December 4th. Finally, ValuEngine raised shares of Bioline RX from a “strong sell” rating to a “sell” rating in a report on Thursday, November 30th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $2.85.
Shares of Bioline RX (NASDAQ BLRX) traded up $0.02 during mid-day trading on Friday, reaching $0.98. 499,274 shares of the company traded hands, compared to its average volume of 583,802. The stock has a market capitalization of $100.05, a price-to-earnings ratio of -3.63 and a beta of 0.15. Bioline RX has a 12 month low of $0.80 and a 12 month high of $1.34.
An institutional investor recently raised its position in Bioline RX stock. Renaissance Technologies LLC raised its position in Bioline RX Ltd (NASDAQ:BLRX) by 60.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 434,700 shares of the biotechnology company’s stock after acquiring an additional 164,500 shares during the period. Renaissance Technologies LLC owned approximately 0.41% of Bioline RX worth $474,000 as of its most recent filing with the Securities & Exchange Commission. 35.39% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This article was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/07/zacks-brokerages-anticipate-bioline-rx-ltd-blrx-will-announce-earnings-of-0-07-per-share.html.
Bioline RX Company Profile
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Get a free copy of the Zacks research report on Bioline RX (BLRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bioline RX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioline RX and related companies with MarketBeat.com's FREE daily email newsletter.